Equity Details
Price & Market Data
Price: $3.02
Daily Change: -$0.123 / 4.07%
Daily Range: $2.98 - $3.20
Market Cap: $6,929,528
Daily Volume: 5,370
Performance Metrics
1 Week: -2.12%
1 Month: -2.75%
3 Months: 42.00%
6 Months: 17.23%
1 Year: -2.43%
YTD: 39.38%
About Xenetic Biosciences, Inc. (XBIO)
Detailed market data for Xenetic Biosciences, Inc. (XBIO) is now available. Priced at 3.02, the stock has recorded a daily change of -$0.123 / 4.07%. Its market capitalization is 6,929,528. Dive into its performance across all listed timeframes, from short-term fluctuations to long-term growth trends.
Company Details
Employees: 2
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.